Vorinostat is an FDA-approved histone deacetylase inhibitor (HDACi) that has proven clinical success in some patients; however, it remains unclear why certain patients remain unresponsive to this agent and other HDACis. Constitutive STAT (signal transducer and activator of transcription) activation, overexpression of prosurvival Bcl-2 proteins and loss of HR23B have been identified as potential biomarkers of HDACi resistance; however, none have yet been used to aid the clinical utility of HDACi. Herein, we aimed to further elucidate vorinostat-resistance mechanisms through a functional genomics screen to identify novel genes that when knocked down by RNA interference (RNAi) sensitized cells to vorinostat-induced apoptosis. A synthetic lethal functional screen using a whole-genome protein-coding RNAi library was used to identify genes that when knocked down cooperated with vorinostat to induce tumor cell apoptosis in otherwise resistant cells. Through iterative screening, we identified 10 vorinostatresistance candidate genes that sensitized specifically to vorinostat. One of these vorinostat-resistance genes was GLI1, an oncogene not previously known to regulate the activity of HDACi. Treatment of vorinostat-resistant cells with the GLI1 smallmolecule inhibitor, GANT61, phenocopied the effect of GLI1 knockdown. The mechanism by which GLI1 loss of function sensitized tumor cells to vorinostat-induced apoptosis is at least in part through interactions with vorinostat to alter gene expression in a manner that favored apoptosis. Upon GLI1 knockdown and vorinostat treatment, BCL2L1 expression was repressed and overexpression of BCL2L1 inhibited GLI1-knockdown-mediated vorinostat sensitization. Taken together, we present the identification and characterization of GLI1 as a new HDACi resistance gene, providing a strong rationale for development of GLI1 inhibitors for clinical use in combination with HDACi therapy.
Epigenetic-based drugs show great promise for treatment of a wide range of cancers. Targeting HDACs has proven effective as a cancer therapy strategy and many new histone deacetylase inhibitors (HDACis) are being developed with varying target specificities. HDACis exert their anticancer effects through a variety of tumor-cell-and non-tumor-cellautonomous effects, and induction of apoptosis is an important mechanism underpinning the anticancer activity of these compounds. Although HDACis have been clinically approved for the treatment of cutaneous T-cell lymphoma and are in advanced clinical trials for other malignancies, many patients remain unresponsive to single-agent HDACi treatment. There exists a need to identify novel genes and pathways that can be targeted in combination with HDACi to improve clinical utility of these compounds. Furthermore, clinical biomarkers are required to predict patient response to inform which patients should receive HDACi therapy.
There have been a number of cellular factors implicated in resistance to HDACi treatment such as drug efflux, alterations in the molecular targets (i.e. HDAC overexpression or mutation), changes in the epigenetic landscape of HDACi target genes, responses to oxidative stress and antiapoptotic and/or prosurvival mechanisms (reviewed in Fantin and Richon 1 ). Hyperactive JAK/STAT (Janus kinase/signal transducer and activator of transcription) signaling can mediate resistance of cutaneous T-cell lymphoma cells to vorinostat. 2 In addition, we and others have demonstrated that overexpression of prosurvival Bcl-2-family proteins protects cells against HDACi-induced apoptosis. [3] [4] [5] [6] HR23B has also been implicated in vorinostat resistance as a protein through which vorinostat induces apoptosis via impaired proteasome function. [7] [8] [9] As the identification of these mechanisms of resistance has not yet impacted the clinical use of HDACi through the generation of combination therapy approaches or clinical biomarkers, a genome-wide study was conducted to identify further mechanisms of resistance to HDACis that may improve the clinical application of these agents.
To elucidate vorinostat-resistance mechanisms, we used human tumor cells with acquired resistance to vorinostat and conducted a protein-coding genome-wide functional genomics screen to identify novel genes that resensitize cells to vorinostat-induced apoptosis. High-throughput RNA interference (RNAi) screening has demonstrated utility for the identification of novel drug targets for cancer therapy and biomarkers for drug response. [10] [11] [12] [13] In addition, screening for synthetic lethality has successfully identified targetable cancer-specific vulnerabilities alone and in combination with existing therapies. [14] [15] [16] [17] [18] [19] [20] [21] The novel identification of GLI1 as a gene that regulates vorinostat-mediated apoptosis and the demonstration that a small-molecule GLI1 inhibitor functions cooperatively with vorinostat to induce tumor cell death provides a new avenue for combination therapies using vorinostat and other HDACis.
Results
Development of tumor cells with acquired resistance to vorinostat and other HDACi. To identify genes that confer resistance to vorinostat, the vorinostat-sensitive HCT116 colon cancer cell line was serially passaged in the presence of vorinostat at apoptotic concentrations resulting in the development of stable vorinostat-resistant cells (HCT116-VR). Compared with HCT116 cells, the HCT116-VR cells were resistant to vorinostat-induced apoptosis as assessed by annexin V staining and assays for DNA fragmentation and caspase-3 activation (Figures 1a-c and Supplementary Figure 1) . The resistance to vorinostat-induced apoptosis was not because of a lack of on-target drug activity within the HCT116-VR cells as equivalent histone H3 hyperacetylation was observed in vorinostat-treated HCT116 and HCT116-VR cells (Figure 1d ). HCT116-VR cells demonstrated relative cross-resistance to the HDACi panobinostat ( Figure 1e) ; however, the cells remained sensitive to apoptosis mediated by the chemotherapeutic drug etoposide (Figure 1f ). Using a cell counting assay over 96 h, HCT116-VR cells cultured in the presence of vorinostat continued to proliferate albeit at a much slower rate compared with vehicle-treated cells (Figure 1g ). Taken together, these data indicate that HCT116-VR cells show acquired and selective apoptotic resistance to the HDACi vorinsostat and panobinostat and therefore represent an appropriate model to screen for genes that mediate the resistance phenotype.
Genome-wide RNAi screens for genes that confer resistance to HDACi-induced apoptosis. Multiple tiers of RNAi screening were used to identify genes that can regulate vorinostat-induced apoptosis. 22 Genes were considered candidate vorinostat-resistance genes if gene knockdown in combination with vorinostat induced cell death of HCT116-VR cells, but gene knockdown alone did not. HCT116-VR cells were robotically transfected in arrayed 384-well format with annotated SMARTpool siRNAs to putatively knockdown all known human protein-coding genes. The cells were subsequently incubated for a further 24 h in the presence and absence of vorinostat. 22 Cell death in the control, minus drug, arm of the screen was assessed with DAPI nuclear staining using high content microscopy. Cell death readouts for the vorinostat-treated plus drug arm of the screen were caspase-3 and -7 activity (Caspase-Glo) and cell viability using CellTitre-Fluor (CTF). The primary SMARTpool siRNA screen yielded 450 gene hits comprising 317 Caspase-Glo 3/7 hits and 150 CTF hits, with 17 genes identified in both assays (Supplementary Figure 2A) . A secondary validation screen was conducted by deconvolution of the SMARTpools into the four individual constituent siRNAs. Of the 450 primary targets, 106 genes validated with high confidence, scoring 2 or more individual siRNAs recapitulating the SMARTpool phenotype (Supplementary Figure 2B) . As a final screen, we identified three human colon cancer cell lines, SW480, SW620 and LIM1215, that demonstrated intrinsic resistance to vorinostat similar to that observed in HCT116-VR cells (Figures 2a and b) . A tertiary knockdown screen of the 106 candidate genes in SW480, SW620 and LIM1215 cells resulted in the identification of 10 genes that specifically conferred resistance to vorinostat in two or more of the four cell lines tested (Supplementary Table 1 ). Nine of the ten vorinostat-resistance candidate genes were hits in the Caspase-Glo assay (GLI1, PSMD13, SAP130, CCNK, CDK10, EIF3L, NFYA, BEGAIN and TOX4) and the tenth hit was identified through the CTF assay (POLR2D). For the nine Caspase-Glo hits, gene knockdown alone induced low or no caspase activation above mock transfection levels; however, upon vorinostat treatment, caspase activity was greatly increased (Figure 2c ).
Complete data sets for each of the primary, secondary and tertiary screens can be found online (PubChem IDs: AID743454, AID743458, AID743448). Specific depletion of target gene mRNA of 490% for all 10 candidate vorinostatresistance genes was confirmed using quantitative real-time PCR (qRT-PCR) (data not shown).
Using the tiered screening approach outlined above, the 10 candidate vorinostat-resistance genes were: GLI1, PSMD13, SAP130, CCNK, CDK10, POLR2D, EIF3L, NFYA, BEGAIN and TOX4. With the exception of two genes, PSMD13 23 and SAP130, 24 these genes had not previously been linked to HDACi activities and represent potentially novel mechanisms of resistance to HDACi. Analysis of RNAseq gene expression profiles upon knockdown of each of these 10 candidates did not identify common signatures or pathway modulation between vorinostat-resistance candidates. 22 As GLI1 has known oncogenic function and pharmacological inhibitors already exist for GLI1 and pathway members, we chose to focus on this candidate for follow-up mechanistic studies.
GLI1 regulates sensitivity to HDACis and this occurs independently of SMO. GLI1 functions as an oncogene in certain contexts through amplification in glioblastoma and alternative splicing in a range of tumors including glioblastoma, breast, prostate, pancreatic and gastric cancers.
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GLI1, however, has not previously been linked to HDACi response or HDACi mechanism of action and was therefore selected for further investigation. Transfection of siGLI1 and treatment with vorinostat showed a significant induction of cell death, as measured by ATP levels using CellTiter-Glo (Promega, Madison, WI, USA) in SW480, SW620 and LIM1215 cell lines consistent with the primary screen phenotype in the HCT116-VR cells (Supplementary Figure  3) . To confirm that GLI1 conferred resistance to HDACimediated apoptosis, the GLI1 small-molecule inhibitor, GANT61, 26, 27 was used in combination with two broadspectrum HDACi, vorinostat and panobinostat. HCT116-VR cells were treated simultaneously with GANT61 and either vorinostat or panobinostat. Pharmacological inhibition of GLI1 successfully phenocopied genetic knockdown of GLI1 resulting in even greater sensitization of HCT116-VR cells to HDACi-induced apoptosis (Figures 3a and b) and a similar outcome was observed for SW480, SW620 and LIM1215 cell lines (Supplementary Figure 3) . The canonical role of GLI1 is as a transcription factor involved in Hedgehog signaling, 25, 28 where upon binding of the Hedgehog ligand to the cell surface receptor Patched (PTCH) releases its inhibitory effect on Smoothened (SMO), which in turn activates GLI1 and a prosurvival and proproliferation transcriptional response. To test for dependence on the Hedgehog pathway in this context, two SMO inhibitors, LDE225 29, 30 and cyclopamine, 31 were evaluated in combination with vorinostat. No GLI1 expression is induced by vorinostat treatment. As vorinostat mediates its effects at least in part through transcriptional mechanisms, the effect of vorinostat treatment on GLI1 expression levels was assessed. GLI1 mRNA was induced by vorinostat (6.1-fold) and panobinostat (5.2-fold) in HCT116-VR cells after 8 h (Figure 4a ). We also observed increased expression of GLI1 mRNA following treatment of parental HCT116 cells with vorinostat (data not shown). Transcriptome analysis (RNAseq) following treatment of HCT116-VR cells with vorinostat indicated that of the 10 candidate vorinostat-resistance genes, GLI1 was the most upregulated candidate upon vorinostat treatment (8.6-fold after 8 h). Furthermore, GLI1 was among the top 10% of all genes upregulated after 4 and 8 h of vorinostat treatment. SMARTpool siRNA-mediated GLI1 knockdown was reduced by 33% in untreated cells and this was sufficient to significantly attenuate the HDACi-induced induction of GLI1 expression (Figure 4a ).
To confirm that GLI1 knockdown did not interfere with the on-target activity of vorinostat, acetylated histone H3 was used as a biomarker of vorinostat activity in HCT116-VR cells transfected with siGL1. HCT116-VR cells with and without GLI1 knockdown were treated with vorinostat or DMSO. Vorinostat treatment induced histone H3 hyperacetylation regardless of GLI1 expression level (Figure 4b ).
GLI1 knockdown and vorinostat treatment shift the balance of prosurvival and proapoptosis genes in favor of apoptosis. As vorinostat induces changes in phenotype at least in part through modulation of transcription 3 and GLI1 is a transcriptional factor, 25 whole-genome transcriptome analysis (RNAseq) was used to investigate potential mechanism(s) of action. HCT116-VR cells were subjected to GLI1 knockdown and then treated with vorinostat or DMSO for 4 h (no cell death detectable) and 8 h (low level of cell death detectable). All conditions were analyzed for differential gene expression compared with mock-transfected, DMSO-treated cells. Complete RNAseq data sets can be found online (Gene Expression Omnibus ID: GSE57871). GLI1 knockdown resulted in reduced expression of validated GLI1 target genes including Cyclin D1, Bcl2, Jagged 2, IL7, FoxF1 and FoxL1 and resulted in fewer gene expression changes than vorinostat treatment. The combination of GLI1 knockdown and vorinostat resulted in more differentially expressed genes than either treatment alone. Pathway enrichment analysis using MetaCore (ThomsonReuters, New York, NY, USA) was conducted on differentially expressed genes in each of the treatment groups for identification of differentially expressed pathways. Both timepoints were analyzed simultaneously, thereby giving greater weight to genes differentially expressed at both timepoints. Apoptosis pathways were enriched in the combination of vorinostat and GLI1 knockdown compared with single treatments (Table 1) .
To investigate the enrichment of apoptosis pathways further, the differential expression values of Bcl-2-family apoptosis genes were extracted from the complete RNAseq data set under each experimental condition and time point ( Figure 5 ). Expression of five prosurvival genes (BCL2, BCL2L1, BCL2L2, MCL1 and BCL2A1) and 14 proapoptotic genes (BCL2L11, BID, BAK1, BAX, BOK, BAD, BIK, BBC3, PMAIP1, BMF, BCL2L13, BCL2L15, HRK and BCL2L10) was assessed. No expression of BCL2A1 or BCL2L10 (DIVA) was detected in this experiment. Vorinostat treatment shifted the balance of pro-and anti-apoptosis genes towards apoptosis and this was due, in part, to a large increase in BMF expression (Figures 5a and b) . GLI1 knockdown also shifted the balance towards apoptosis because of induction of a range of pro-apoptosis genes including BMF, BAX, BIK, BBC3 (PUMA), PMAIP1 (NOXA) and BCL2L15 (BFK) and downregulation of BCL2L1 (BCLXL) (Figures 5c and d) . Taken together, the combination of GLI1 knockdown and vorinostat treatment resulted in greater induction of pro-apoptosis genes such as upregulation of BCL2L11 (BIM) and greater suppression of pro-survival genes such as BCL2L1 (Figures 5e and f) . This supports the identification of apoptosis pathways in the enrichment analysis and identified a shift in expression of pro-and anti-apoptosis genes in favor of apoptosis as a result of vorinostat treatment and GLI1 knockdown.
BCL2L1 transcriptional regulation is functionally important for GLI1 knockdown-mediated sensitization to vorinostat-induced apoptosis. The functional effect of the antiapoptotic Bcl-2-family gene, BCL2L1, in mediating GLI1-regulated sensitization to vorinostat was assessed by stably overexpressing BCL2L1 in HCT116-VR cells concurrently with GLI1 knockdown and vorinostat treatment. HCT116-VR cells were stably transduced with a GFP or 
Discussion
The biological effects and mechanisms of action of HDACis are extremely broad and there may be many mechanisms by which tumor cells exhibit or acquire resistance to these agents. Through whole-genome functional screening, GLI1 was identified as a novel vorinostat-resistance gene. The importance of GLI1 in regulating vorinostat-mediated apoptosis was originally discovered through a screen in the setting of acquired resistance to vorinostat using HCT116-VR cells. However, using other solid tumor cells that were intrinsically resistant to vorinostat (LIM1215, SW480, SW620), we showed that the importance of GLI1 as a regulator of vorinostat sensitivity was more widespread. A synthetic lethal interaction between GLI1 knockdown and vorinostat treatment resulted in changes in expression of genes that directly regulate apoptosis. 3, 32 Many studies have demonstrated the ability of HDACi to regulate apoptosis gene expression in favor of apoptosis and this is important in HDACi mechanism of action (reviewed in Bolden et al. 3 and Falkenberg and Johnstone 33 ). Although vorinostat treatment alone induced gene expression changes in HCT116-VR cells in favor of apoptosis, these were clearly not sufficient to induce cell death. However, following GLI1 knockdown, this balance between pro-survival and pro-apoptosis gene expression was shifted further in favor of apoptosis, resulting in death of previously vorinostat-resistant cells. A working model is presented in Figure 6c .
Baseline expression levels of GLI1 in HCT116-VR cells were low and these were markedly increased upon vorinostat treatment. A similar induction of GLI1 was observed in MEFs treated with the pan-HDACi trichostatin A. 34 The canonical role of GLI1 is as a key transcription factor and effector molecule in the Hedgehog signaling pathway. 25 As SMO inhibition did not sensitize to vorinostat-induced apoptosis, GLI1 appears to function through a noncanonical pathway in this system. Other studies have also identified SMO-independent GLI1 dependence in cancer (reviewed in Shevde and Samant 35 ), such as the SMO-independent role of GLI1 in neuroblastoma demonstrated using pharmacological and genetic approaches. 36 GLI1 function is regulated through acetylation and ubiquitination. 37 Unlike its family members, GLI1 is a constitutive transcriptional activator and proteasomal cleavage results in degradation of the protein.
38,39 GLI1 transcriptional activity is enhanced by HDAC1-mediated deacetylation leading to enhanced cellular proliferation and transformation. 40 An E3 ubiquitin ligase complex containing Cullin3, REN, KCASH2 and KCASK3 leads to HDAC1 degradation and reverses this phenotype. 40, 41 As vorinostat inhibits HDAC1, the effect of vorinostat and GLI1 knockdown on GLI1 function may be a combination of indirect GLI1 inhibition through inhibition of HDAC1 and prevention of GLI1 induction through GLI1 knockdown. Epigenetic repression of GLI1 expression occurs in part through histone methylation. Menin recruits PRMT5 to the GLI1 promoter to lay down the H4R3me2 repressive mark in a Hedgehog signalingindependent manner 42 and a recently identified noncoding RNA induces H3K27me3 at the GLI1 promoter, thereby reducing RNA polymerase II recruitment. GLI1 has frequently been implicated in cancer cell therapy resistance through decreased chemotherapy and radiotherapy responsiveness [44] [45] [46] [47] [48] and increased expression of cell surface drug transporters. [49] [50] [51] Recently, GLI1 was shown to drive resistance of AML cells to ribavirin and cytarabine through UGT1A-dependent glucuronidation of the compounds and inhibition of GLI1 with GANT61 restored sensitivity. 52 Additionally, SMO-independent GLI1 activity is important for adjusted p value < 0.05 adjusted p value ≥ 0.05 These studies provide strong evidence for the role of GLI1 in tumor cell resistance to a range of anticancer therapies; however, this is the first study to identify a role for GLI1 in response to HDACi. The noncanonical regulation of GLI1 in this system highlights the need for the generation of GLI1 inhibitors, where SMO inhibitors that are receiving much clinical attention would be ineffective. GLI1 is known to positively regulate expression of BCL2 through direct promoter binding 53, 54 and herein we show the downregulation of BCL2 upon GLI1 knockdown. GLI2 is a more potent activator of BCL2 expression than GLI1, 55 which may explain the subtle transcription repression observed (1.6-fold). Bolden et al. 5 previously described a tumor-cellselective pro-apoptosis gene expression signature upon vorinostat treatment of paired normal and tumorigenic human fibroblasts. Vorinostat treatment of BJ LTSTERas fibroblasts resulted in repression of BCL2L1 (BCLXL) and BCL2L2 (BCLW), which was also observed in the vorinostat-treated HCT116-VR cells in this study, indicating a potentially conserved transcriptional response to vorinostat treatment in transformed cells. Similarly, a similar panel of proapoptotic genes was induced in both studies including BCL2L11 (BIM), BAD, PMAIP1 (NOXA) and BAK1. Induction of BMF expression by vorinostat in lymphoma cells has also been previously observed. 56 Based on our studies, we posit that combination therapy approaches involving HDACi and GLI1 inhibitors merit further investigation. At present, there is no small-molecule inhibitor of GLI1 appropriate for use in humans and this is a major hurdle before combination therapies consisting of GLI1 and HDAC inhibition can be trailed. Given the noncanonical activation of GLI1 observed in this study and in many others, there is a strong rationale for development of GLI1 inhibitors to complement significant efforts currently focusing on SMO inhibitors. 57 Materials and Methods Reagents. HDACis, vorinostat and panobinostat, were obtained directly from the manufacturers Merck (Boston, MA, USA) and Novartis (Cambridge, MA, USA), respectively. The GLI1 inhibitor, GANT61, was obtained from Sigma (St Louis, MO, USA) (cat. no. G9048). SMO inhibitors, LDE225 and cyclopamine (cat. no. C4116), were obtained from Novartis and Sigma, respectively. siRNA screening. A detailed description of the methods used in the siRNA screen has been described previously. 22, 58 Briefly, HCT116-VR cells were reverse transfected on day 1, media changed on day 2, treated with vorinostat or vehicle (DMSO) on day 3 and assessed for cell death on day 4. The two parallel arms of the screen (plus and minus drug) evaluated cell death using different measurements. The plus drug arm was evaluated for general viability using CTF (Promega) and apoptosis using Caspase-Glo 3/7 (Promega). The minus drug arm was subjected to nuclear staining by DAPI (Invitrogen, Carlsbad, CA, USA) followed by high content cell counting as a surrogate readout of cell death.
Cell culture and transfection. Vorinostat-resistant HCT116 colon carcinoma cells (HCT116-VR) were a kind gift from Merck Research Laboratories (Boston, MA, USA) and were generated by culturing the parental line in increasing concentrations of vorinostat until a vorinostat-resistant line was established. Cells were cultured in RMPI containing GlutaMAX (Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS, 2.5 g/l glucose and 1% (v/v) sodium pyruvate in humidified incubators at 37°C and 5% CO 2 . Cells were reverse transfected with DharmaFECT2 (GE, Pittsburgh, PA, USA) as follows: 6-well plate -1.5 μl, 1. lines were cultured in RPMI-1640 containing 10% FBS and were transfected with the siGLI1 SMARTpool (40 nM) using DharmaFECT 2 (0.1 μl per well for each line) in parallel using high-throughput liquid handling in 384-well format. Plates were poly-L-lysine treated before addition of cells, as per Falkenberg et al. 22 At 48 h after transfection, cells were treated with vorinostat (2.5 μM) or DMSO and cell viability measured at 24, 48 and 72 h after drug treatment using CellTiter-Glo, an end-point luminescence reagent that quantitates cellular ATP using a plate reader (Promega).
Drug treatments and cell viability assay. Capase-Glo 3/7 and CTF assays were conducted in 384-well format. 22, 58 CTF buffer and substrates were combined and 5 μl was added to wells containing 20 μl cells and media. Plates were incubated at 37°C for 1.5 h and fluorescence quantified (excitation: 380-400 nm and emission: 505 nm). Caspase-Glo 3/7 reagent and substrate were combined and 12 μl added to each well before incubation at room temperature for 30 min followed by luminescence quantification. Readings were taken on the Synergy H4 Hybrid Multi-mode Microplate Reader (BioTek, Winooski, VT, USA).
For drug combination assays, cells were treated with both drugs concurrently for 48 h before harvesting for annexin V staining. Doses of drugs used were: 1-2.5 μM vorinostat, 5-50 nM panobinostat, 1-20 μM LDE225 and 1-20 μM cyclopamine. For vorinostat treatment of BCL2L1-overexpressing cells, 0.1-5 μM was used. For flow cytometry analysis of apoptosis, cells were resuspended in 100 μl annexin-V-binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM CaCl 2 ) containing 1/100 dilution of annexin-V-APC (BD Biosciences, North Ryde, NSW, Australia) and 1/100 dilution propidium iodide (PI) citrate buffer (69 mM PI (Sigma), 38.8 mM sodium citrate).
For the cell counting assay, HCT116 and HCT116-VR cells were seeded in 24-well plates and treated with 2.5 μM vorinostat or DMSO. Every 24 h, triplicate wells were trypsinised and counted using trypan blue and a haemocytometer.
For the drug combination studies performed in the SW480, SW620 and LIM1215 cell lines, cells were plated using liquid handling automation at the same density reported for siRNA transfections above. At 48 h after seeding, cells were treated with DMSO, vorinostat alone (2.5 μM), GANT61 alone (15 and 20 μM doses) and in combination. There were six replicate wells per treatment condition. Cell viability was measured using CellTiter-Glo as described above.
BCL2L1 overexpression. MSCV-GFP and MSCV-GFP-BCL2L1 constructs were previously generated in the laboratory. Retrovirus was packaged by calcium phosphate-transfected Phoenix E cells and used to transduce HCT116-VR cells. Cells were sorted for medium-high GFP expression and western blot was used to confirm overexpression.
Western blot analysis. Cells were lysed with 25 mM HEPES, 250 mM NaCl, 2.5 mM EDTA, 0.1% Triton-X 100, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin and 0.5 mM phenylmethylsulfonyl fluoride, and protein concentration was determined with a BCA assay (Pierce, Rockford, IL, USA). Equal amounts of protein per sample were separated by SDS-PAGE and transferred to an Immobilon-P PVDF membrane (Millipore, Bedford, MA, USA). Membranes were blocked with 5% skim milk in TBS-T, followed by incubation with antibodies. Primary antibodies were diluted in blocking buffer: β-actin (Sigma; cat. no. A2228), acetylated histone H3 (EMD Millipore, Billerica, MA, USA; cat. no. 06-599), BCL2L1 (Santa Cruz, Castle Hill, NSW, Australia; cat. no. 8392) and incubated at 4°C overnight. Secondary antibodies (Dako, Campbellfield, VIC, Australia) were incubated in blocking buffer for 1 h at RT before detection of protein with enhanced chemoluminescence reagents (Amersham ECL, Amersham ECL Plus) and Fuji film (Super RX).
qRT-PCR. Total RNA was isolated from cells using the RNeasy Plus Mini Kit (Qiagen, Doncaster, VIC, Australia). cDNA was prepared using random primers and MMLV reverse transcriptase (Promega). qRT-PCR was performed on the 7900 HT Fast Real Time PCR system with SDS v.2.3 software (Applied Biosystems, Forster City, CA, USA) using the SYBR green detection method. A standard curve was generated in each run for each primer and results were analyzed using the adjusted Ct method followed by normalization to the housekeeping gene, L32. qRT-PCR primers: GLI1 forward -5′-AAGCGTGAGCCTGAATCTGT-3′ and GLI1 reverse -5′-CAGCATGTACTGGGCTTTGA-3′; L32 forward -5′-TTCCTGGTCCACAACG TCAAG-3′ and L32 reverse -5′-TGTGAGCGATCTCGGCAC-3′.
Next-generation sequencing. RNA was prepared for sequencing on the Illumina HighSeq 2000 using the proprietary TruSeqTM RNA Sample Preparation v2 Guide with all kit reagents purchased from Illumina (San Diego, CA, USA). RNAseq reads were aligned to the human reference genome (Homo_sapiens.GRCh37.67.gtf (from ENSEMBL release 67)) using TopHat/Bowtie. 59 Sample quality control was performed simultaneously with the FastQC program (Babraham Bioinformatics, Babraham Institute, Cambridge, UK). Read counting was performed with HTSeq. 60 Differential gene expression analysis was performed using EdgeR 61 and limmavoom. 62 All treatment samples were compared with mock transfection and differential gene expression was defined as log 2 fold change ⩾ 1 or ⩽ − 1 and adjusted P-value o0.05.
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